Status:
ACTIVE_NOT_RECRUITING
Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Conditions:
Anatomic Stage 0 Breast Cancer AJCC V8
Anatomic Stage I Breast Cancer AJCC V8
Eligibility:
FEMALE
15-39 years
Phase:
NA
Brief Summary
This clinical trial compares a web-based patient-reported symptom monitoring and self management portal, the Young, Empowered \& Strong (YES), to standard therapy in managing symptoms in adolescent an...
Detailed Description
PRIMARY OBJECTIVES: I. To determine the efficacy of the YES intervention compared to usual care in improving quality of life (QOL), as measured by the Quality of Life in Adult Cancer Survivors (QLACS...
Eligibility Criteria
Inclusion
- Female
- Age 15-39 years at diagnosis of a stage 0-III breast cancer
- Within 3 years of breast cancer diagnosis
- No known evidence of breast cancer recurrence (local or distant) or second primary breast cancer
- No prior history of new other malignancy since their breast cancer diagnosis (other than non-melanoma skin cancer)
- Able to speak, understand and read English
- Cognitively able to complete the study requirements
- Ability to access medical records from treating hospital
- Willing to provide cell phone number and/or email address, and willing to receive email and/or text messages from the study team either with their own smartphone or one provided by the study team if they do not have their own to use
- Pregnant survivors are also eligible for this protocol, given that fertility and pregnancy are important AYA issues
Exclusion
- Individuals under age 15 or over age 42
- Stage IV or metastatic breast cancer
- Males with breast cancer are not being recruited to this protocol. In the AYA age group, only a miniscule proportion of breast cancers occur in males. For this reason, the YES portal intervention materials have been targeted for young women
Key Trial Info
Start Date :
June 28 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2026
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04906200
Start Date
June 28 2021
End Date
August 31 2026
Last Update
March 6 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
2
Columbia University Medical Center
New York, New York, United States, 10032
3
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210